FRANKFURT (Reuters) – Drugmaker Bayer said on Wednesday that initial testing on humans showed that its experimental stem cell therapy to treat Parkinson’s disease was well-tolerated and that transplanted cells survived in patients’ brains.
Bayer said the positive one-year results from subsidiary BlueRock Therapeutics’s Phase I trial of the stem cell-based therapy bemdaneprocel encouraged it to advance the testing on humans to the second of three stages.
(Reporting by Ludwig Burger; Editing by Miranda Murray)
